DK2343304T3 - Biocide boronophthalidforbindelser - Google Patents

Biocide boronophthalidforbindelser Download PDF

Info

Publication number
DK2343304T3
DK2343304T3 DK11154575.2T DK11154575T DK2343304T3 DK 2343304 T3 DK2343304 T3 DK 2343304T3 DK 11154575 T DK11154575 T DK 11154575T DK 2343304 T3 DK2343304 T3 DK 2343304T3
Authority
DK
Denmark
Prior art keywords
benzoxaborol
hydroxy
compound
dihydro
nail
Prior art date
Application number
DK11154575.2T
Other languages
English (en)
Inventor
Stephen Baker
Tsutomu Akama
Carolyn Bellinger-Kawahara
Vincent Hernandez
Karin Hold
James Leyden
Kirk Maples
Jacob Plattner
Virginia Sanders
Yong-Kang Zhang
Original Assignee
Anacor Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36917059&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2343304(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anacor Pharmaceuticals Inc filed Critical Anacor Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2343304T3 publication Critical patent/DK2343304T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/05—Cyclic compounds having at least one ring containing boron but no carbon in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (38)

  1. (Ilb) PATENTKRAV 1. Forbindelse til terapeutisk anvendelse, hvilken forbindelse har en struktur ifølge formel (Ilb):
    hvor R7b er et element udvalgt fra H, methyl, ethyl og phenyl; R10b er et element udvalgt fra H, OH, NH2, SH, halogen, substitueret eller ikke-substitueret phenoxy, substitueret eller ikke-substitueret phenylalkyloxy, substitueret eller ikke-substitueret phenylthio og substitueret eller ikke-substitueret phenylalkylthio; og Rllb er et element udvalgt fra H, OH, NH2, SH, methyl, substitueret eller ikke-substitueret phenoxy, substitueret eller ikke-substitueret phenylalkyloxy, substitueret eller ikke-substitueret phenylthio og substitueret eller ikke-substitueret phenylalkylthio, hvor begrebet "alkyl" en en Ci-Cio-alkylgruppe; hvor substituenter for de forskellige opførte alkylgrupper er udvalgt fra: -OR', =0, =NR', =N-OR’, -NR'R", -SR’, -halogen, -0C(0)R’, -C(0)R', -C02R', -CONR'R", -0C(0)NR’R", -NR"C(0)R', -NR'-C(0)NR"R"', -NR"C(0)2R’, -NR-C(NR’R"R'")=NR"", -NR-C(NR'R")=NR"', -S(0)R', -S(0)2R', -S(0)2NR'R", -NRS02R', -CN og -N02 i et antal, der ligger fra nul til (2m'+l), hvor m’ er det totale antal carbonatomer i en sådan radikal, og hvor R', R", R"' og R"" hver uafhængigt henviser til hydrogen-, heteroalkyl-, aryl-, alkyl-, alkoxy-, thioalkoxy- eller arylalkylgrupper; og hvor substituenter for de forskellige opførte substituerede arylgrupper er udvalgt fra gruppen bestående af: halogen, -OR’, =0, =NR', =N-OR’, -NR’R", -SR’, -0C(0)R’, -C(0)R’, -C02R’, -CONR'R", -0C(0)NR'R", -NR"C(0)R', -NR'-C(0)NR"R"', - NR"C(0)2R', -NR- C(NR'R"R"’)=NR"", -NR-C(NR'R")=NR"', -S(0)R’, -S(0)2R’, - S(0)2NR’R", -NRS02R’, -CN og -N02, -R', -N3, -CH(Ph)2, fluor(Ci-C4)alkoxy og fluor(Ci-C4)alkyl, i et antal, der ligger fra nul til det totale antal åbne valenser; og hvor R', R", R"' og R"" uafhængigt er udvalgt fra hydrogen, alkyl, heteroalkyl, aryl og heteroaryl.
  2. 2. Forbindelse til anvendelse ifølge krav 1, hvor R10b er et element udvalgt fra OH, NH2, SH, halogen, substitueret eller ikke-substitueret phenoxy, substitueret eller ikke-substitueret phenylalkyloxy, substitueret eller ikke-substitueret phenylthio og substitueret eller ikke-substitueret phenylalkylthio.
  3. 3. Forbindelse til anvendelse ifølge krav 1, hvor ét element udvalgt Ira R10b og Rllb er H og det andet element udvalgt fra R10b og Rllb er et element udvalgt fra halo, methyl og p-cyanphenyloxy.
  4. 4. Forbindelse til anvendelse ifølge krav 1, hvor R7b er H.
  5. 5. Forbindelse til anvendelse ifølge krav 1, hvor R10b er substitueret phenoxy.
  6. 6. Forbindelse til anvendelse ifølge krav 1, hvor R1 lb er H.
  7. 7. Forbindelse til anvendelse ifølge krav 1, der er et element udvalgt fra 5-(4-cyanphenoxy)-l,3- dihydro-l-hydroxy-2,l-benzoxaborol, 6-(4-cyanphenoxy)-l,3-dihydro-l-hydroxy-2,l- benzoxaborol, 6-(3 -cyanphenoxy)-1,3 -dihydro-1 -hydroxy-2,1 -benzoxaborol, 6-(4- chlorphenoxy)-1,3-dihydro-1 -hydroxy-2,1 -benzoxaborol, 5-(4-cyanobenzyloxy)-l,3-dihydro-l -hydroxy-2,1-benzoxaborol, 5-(2-cyanphenoxy)-l,3-dihydro-l-hydroxy-2,1-benzoxaborol, 5-[4-(N,N-diethylcarbamoyl)phenoxy]-l,3-dihydro-l -hydroxy-2,1 -benzoxaborol, 1,3-dihydro-l - hydroxy-5-[4-(morpholincarbonyl)phenoxy]-2,l-benzoxaborol, 5-(3,4-dicyanphenoxy)-l,3-dihydro-1 -hydroxy-2,1 -benzoxaborol, 6-phenylthio-1,3 -dihydro-1 -hydroxy-2,1 -benzoxaborol, 6-(4-trifluormethoxyphenoxy)-1,3 -dihydro-1 -hydroxy-2,1 -benzoxaborol, 6-(4- methoxyphenoxy)-l,3-dihydro-l-hydroxy-2,1-benzoxaborol, 6-(4-methoxyphenylthio)-l,3-dihydro-1 -hydroxy-2,1 -benzoxaborol, 5-(3 -cyanphenoxy)-1,3-dihydro-1 -hydroxy-2,1 - benzoxaborol, 5-(4-carboxyphenoxy)-1 -hydroxy-2,1 -benzoxaborol, 1 -hydroxy-5-[4-(tetrazol-1 -yl)phenoxy]-2,1 -benzoxaborol.
  8. 8. Forbindelse til anvendelse ifølge krav 1, der er et element udvalgt fra 5-(4-cyanphenoxy)-l,3- dihydro-1 -hydroxy-2,1 -benzoxaborol, 6-(4-cyanphenoxy)-l ,3-dihydro-1 -hydroxy-2,1 - benzoxaborol, 6-(3 -cyanphenoxy)-1,3 -dihydro-1 -hydroxy-2,1 -benzoxaborol, 5-(2- cyanphenoxy)-l,3-dihydro-l-hydroxy-2,1-benzoxaborol, 5-(3,4-dicyanphenoxy)-l,3-dihydro-l-hydroxy-2,1 -benzoxaborol og 5-(3-cyanphenoxy)-l,3-dihydro-1 -hydroxy-2,1 -benzoxaborol.
  9. 9. Forbindelse til anvendelse ifølge krav 1, der er 5-(4-cyanphenoxy)-1,3-dihydro-1-hydroxy-2,1-benzoxaborol.
  10. 10. Forbindelse til anvendelse ifølge krav 1, der er 5-(3,4-dicyanphenoxy)-l,3-dihydro-l-hydroxy-2, 1 -benzoxaborol.
  11. 11. Forbindelse til anvendelse ifølge et hvilket som helst af de foregående krav i en form, der er et element udvalgt lfa et hydrat med vand, et solvat med en alkohol, et addukt med en aminoforbindelse og et addukt med en syre.
  12. 12. Forbindelse til terapeutisk anvendelse, hvilken forbindelse er som defineret i et hvilket som helst af kravene 1 til 10 i form af et farmaceutisk acceptabelt salt, eventuelt hvor saltet er et baseadditionssalt opnået ved at etablere kontakt mellem den neutrale form af en sådan forbindelse med en tilstrækkelig mængde af den ønskede base i et egnet inert opløsningsmiddel.
  13. 13. Farmaceutisk formulering omfattende: a) en forbindelse som defineret i et hvilket som helst af kravene 1 til 10; og b) en farmaceutisk acceptabel excipiens deraf.
  14. 14. Farmaceutisk formulering ifølge krav 13, hvor excipiensen er et farmaceutisk acceptabelt topisk bærestof.
  15. 15. Farmaceutisk formulering ifølge krav 13 eller krav 14, hvor formuleringen er et element udvalgt fra en lak, lotion, cream, gel, salve, stick, pasta, skum, mousse og spray, eventuelt hvor formuleringen er en salve og endvidere eventuelt hvor sprayen tilvejebringer forbindelsen ifølge et hvilket som helst af kravene 1 til 10 i en vandig og/eller alkoholopløsning.
  16. 16. Farmaceutisk formulering ifølge et hvilket som helst af kravene 13 til 15, hvor formuleringen endvidere omfatter ét eller flere elementer udvalgt fra et emulgeringsmiddel, blødgøringsmiddel, antioxidant, konserveringsmiddel, chelateringsmiddel, neutraliseringsmiddel, viskocitetsforbedrende middel, penetrationsforbedrende middel, antiinflammatorisk middel, vitamin, antiældningsmiddel, en solcreme og et acnebehandlingsmiddel, og/eller hvor formuleringen endvidere omfatter et element udvalgt fra gruppen bestående af et fortykningsmiddel, en gelfasebærer, neglepenetrationsforbedrende middel og et viskocitetsforbedrende middel.
  17. 17. Farmaceutisk formulering ifølge et hvilket som helst af kravene 13 til 16, hvor formuleringen omfatter et chelateringsmiddel, eventuelt hvor chelateringsmidlet er udvalgt fra gruppen udvalgt fra citronsyre, ethylendiamintetraeddikesyre (EDTA), ethylenglycol-bis(beta-aminoethylether)- N, N,N',N'tetraeddikesyre (EGTA) og 8-amino-2-[(2-amino-5-methylphenoxy)methyl]-6-methoxyquinolin-N,N,N',N'-tetraeddikesyre, tetrakaliumsalt (QUIN-2), og/eller hvor chelateringsmidlet er til stede i en mængde på mellem 0,005 % til 2 vægt-%.
  18. 18. Farmaceutisk formulering ifølge krav 17, hvor chelateringsmidlet er ethylendiamintetraeddikesyre.
  19. 19. Farmaceutisk formulering ifølge et hvilket som helst af kravene 13 til 18, hvor formuleringen omfatter en antioxidant, eventuelt hvor antioxidanten er udvalgt fra gruppen bestående af butyleret hydroxytoluen, ascorbinsyre, natriumascorbat, calciumascorbat, ascorbinpalmitat, butyleret hydroxyanisol, 2,4,5-trihydroxybutyrophenon, 4-hydroxymethyl-2,6-di-fert-butylphenol, erythorbinsyre, guajakharpiks, propylgallat, thiodipropionsyre, dilaurylthiodipropionat, tert-butylhydroquinon og tocopheroler, såsom vitamin E, og lignende, indbefattende farmaceutisk acceptable salte og estere af disse forbindelser, eventuelt hvor antioxidanten er butyleret hydroxytoluen, og endvidere eventuelt hvor antioxidanten er til stede i en mængde på fra ca. 0,001 til 0,5 vægt-%, fortrinsvis 0,05 til ca. 0,5 vægt-%, mere fortrinsvis O, 1 %.
  20. 20. Farmaceutisk formulering ifølge et hvilket som helst af kravene 13 til 19, hvor formuleringen omfatter petroleum eller petroleumderivat, og/eller hvor formuleringen omfatter et element udvalgt fra cetearylalkohol, cetylalkohol, stearylalkohol, emulgerende voks, glycerylmonostearat, glyceryldistearat, ethylenglycoldistearat, sorbitantristearat, propylenglycolmonostearat, sorbitanmonooleat, sorbitanmonostearat, diethylenglycolmonolaurat, sorbitanmonopalmitat, saccharosedioleat, saccharosestearat, polyoxyethylenlaurylether, polyoxyethylen (2) stearylether, polyoxyethylen (21) stearylether, polyoxyethylenmonostearat, polyoxyethylensorbitanmonostearat, polyoxyethylensorbitanmonooleat, polyoxyethylensorbitanmonolaurat og natriumoleat, og/eller hvor formuleringen omfatter glycerylmonostearat eller glyceryldistearat, og/eller hvor formuleringen omfatter voks, og/eller hvor formuleringen omfatter alkohol og/eller hvor formuleringen omfatter alkohol og vand.
  21. 21. Farmaceutisk formulering ifølge et hvilket som helst af kravene 13 til 20, hvor formuleringen omfatter ét eller flere elementer udvalgt fra ethanol og propylenglycol.
  22. 22. Farmaceutisk formulering ifølge krav 13, hvilken formulering omfatter: ca. 20 % propylenglycol; ca. 70 % ethanol og ca. 10 % af forbindelsen; eller ca. 70 % ethanol; ca. 20 % poly(vinylmethylether-alt-maleinsyre monobutylester) og ca. 10 % af forbindelsen, eller ca. 56 % ethanol; ca. 14 % vand; ca. 15 % poly(2-hydroxyethylmethacrylat); ca. 5 % dibutylsebacat og ca. 10 % af forbindelsen, eller ca. 55 % ethanol; ca. 15 % ethylacetat; ca. 15 % poly(vinylacetat); ca. 5 % dibutylsebacat og ca. 10 % af forbindelsen.
  23. 23. Farmaceutisk formulering ifølge et hvilket som helst af kravene 13 til 21, hvor forbindelsen er til stede i formuleringen i en koncentration fra ca. 0,5 % til ca. 15 % vægt/volumen, eventuelt, fra ca. 0,1 % til ca. 12,5 % vægt/vo lumen, eventuelt, fra ca. 1 % til ca. 5 % vægt/vo lumen, eventuelt, fra ca. 2 % til ca. 8 % vægt/volumen, og eventuelt, fra ca. 4 % til ca. 9 % vægt/volumen.
  24. 24. Farmaceutisk formulering ifølge et hvilket som helst af kravene 13 til 21, hvor forbindelsen er til stede i en form, der er et element udvalgt fra et hydrat med vand, et solvat med en alkohol, et addukt med en aminoforbindelse og et addukt med en syre.
  25. 25. Farmaceutisk formulering ifølge et hvilket som helst af kravene 13 til 24, hvor den farmaceutiske formulering er beregnet til administration på et sted, der er hud eller negl, eller hår, eller hud, der omgiver neglen, eller hud, der omgiver håret.
  26. 26. Farmaceutisk formulering ifølge et hvilket som helst af kravene 13 til 24, hvor den farmaceutiske formulering administreres til et dyr, der er udvalgt fra gruppen bestående af et menneske, kvæg, ged, gris, får, hest, ko, tyr, hund, marsvin, løbemus, kanin, kat, kylling og kalkun, eventuelt hvor dyret er et menneske.
  27. 27. Farmaceutisk formulering ifølge et hvilket som helst af kravene 13 til 26, hvilken formulering endvidere indbefatter et supplerende farmaceutisk effektivt middel, hvor formuleringen er en topisk farmaceutisk formulering, og hvor formuleringen endvidere indbefatter et anti-inflammatorisk middel udvalgt fra gruppen bestående af: bisabolol, mentholatum, dapson, aloe og hydrocortison.
  28. 28. Forbindelse der er et element udvalgt fra 5-(4-cyanphenoxy)-l,3-dihydro-l-hydroxy-2,1- benzoxaborol, 6-(4-cyanphenoxy)-1,3 -dihydro-1 -hydroxy-2,1 -benzoxaborol, 6-(3- cyanphenoxy)-1,3-dihydro-1 -hydroxy-2,1 -benzoxaborol, 6-(4-chlorphenoxy)-1,3-dihydro-1 - hydroxy-2,1 -benzoxaborol, 5-(4-cyanobenzyloxy)-1,3 -dihydro-1 -hydroxy-2,1 -benzoxaborol, 5- (2- cyanphenoxy)-l ,3-dihydro-l-hydroxy-2,l-benzoxaborol, 5-[4-(N,N- diethylcarbamoyl)phenoxy]-l ,3-dihydro-l -hydroxy-2,1 -benzoxaborol, 1,3-dihydro-l -hydroxy-5-[4-(morpholincarbonyl)phenoxy] -2,1 -benzoxaborol, 5-(3,4-dicyanphenoxy)-1,3 -dihydro-1 - hydroxy-2,1 -benzoxaborol, 6-phenylthio-1,3 -dihydro-1 -hydroxy-2,1 -benzoxaborol, 6-(4- trifluormethoxyphenoxy)-l,3-dihydro-l-hydroxy-2,1-benzoxaborol, 6-(4-methoxyphenoxy)- 1,3 -dihydro-1 -hydroxy-2,1 -benzoxaborol, 6-(4-methoxyphenylthio)-1,3 -dihydro-1 -hydroxy- 2, 1 -benzoxaborol, 5-(3 -cyanphenoxy)-l ,3-dihydro-1 -hydroxy-2,1 -benzoxaborol, 5-(4- carboxyphenoxy)-l -hydroxy-2,1 -benzoxaborol, 1 -hydroxy-5-[4-(tetrazol-1 -yl)phenoxy] -2,1 - benzoxaborol.
  29. 29. Forbindelse ifølge krav 28, der er et element udvalgt fra -(4-cyanphenoxy)-l,3-dihydro-l-hydroxy-2,1 -benzoxaborol, 6-(4-cyanphenoxy)-l,3-dihydro-l -hydroxy-2,1 -benzoxaborol, 6-(3-cyanphenoxy)-l,3-dihydro-l-hydroxy-2,l-benzoxaborol, 5-(2-cyanphenoxy)-l,3-dihydro-l-hydroxy-2,1 -benzoxaborol, 5-(3,4-dicyanphenoxy)-l ,3-dihydro-l -hydroxy-2,1 -benzoxaborol og 5-(3 -cyanphenoxy)-1,3 -dihydro-1 -hydroxy-2,1 -benzoxaborol.
  30. 30. Forbindelse ifølge krav 28, der er 5-(4- cyanphenoxy)-l,3-dihydro-l-hydroxy-2,l- benzoxaborol.
  31. 31. Forbindelse ifølge krav 28, der er 5-(3,4-dicyanphenoxy)-l,3-dihydro-l-hydroxy-2,l- benzoxaborol.
  32. 32. Forbindelse ifølge et hvilket som helst af kravene 28 til 31 i en form, der er et element udvalgt fra et hydrat med vand, et solvat med en alkohol, et addukt med en aminoforbindelse og et addukt med en syre.
  33. 33. Forbindelse som defineret i et hvilket som helst af kravene 28 til 31 i form af et farmaceutisk acceptabelt salt, eventuelt hvor saltet er et baseadditionssalt opnået ved at etablere kontakt mellem den neutrale form af en sådan forbindelse med en tilstrækkelig mængde af den ønskede base i et egnet inert opløsningsmiddel
  34. 34. Topisk gelformulering omfattende: (a) en forbindelse som defineret i et hvilket som helst af kravene 1 til 10 og (b) en gelfasebærer.
  35. 35. Forbindelse som defineret i et hvilket som helst af kravene 1 til 12 eller a farmaceutisk formulering ifølge et hvilket som helst af kravene 13 til 27 til topisk administration.
  36. 36. Forbindelse som defineret i et hvilket som helst af kravene 1 til 12 eller farmaceutisk formulering ifølge et hvilket som helst af kravene 13 til 27 til anvendelse i behandlingen af inflammation.
  37. 37. Anvendelse af 5-(4-cyanphenoxy)-l,3-dihydro-l-hydroxy-2,l-benzoxaborol, eller et farmaceutisk acceptabelt salt deraf, og en farmaceutisk acceptabel excipiens deraf til fremstilling af en farmaceutisk formulering comprising 5-(4-cyanphenoxy)-l,3-dihydro-l-hydroxy-2,l-benzoxaborol, eller et farmaceutisk acceptabelt salt deraf, og den farmaceutisk acceptable excipiens, eventuelt hvor saltet er et baseadditionssalt opnået ved at etablere kontakt mellem den neutrale form af forbindelsen og en tilstrækkelig mængde af den ønskede base i et egnet inert opløsningsmiddel.
  38. 38. Anvendelse af 5-(3,4-dicyanphenoxy)-l,3-dihydro-l-hydroxy-2,l-benzoxaborol, eller et farmaceutisk acceptabelt salt deraf, og en farmaceutisk acceptabel excipiens deraf til fremstilling af en farmaceutisk formulering omfattende 5-(3,4-dicyanphenoxy)-l,3-dihydro-l-hydroxy-2,l-benzoxaborol, eller et farmaceutisk acceptabelt salt deraf, og den farmaceutisk acceptable excipiens, eventuelt hvor saltet er et baseadditionssalt opnået ved at etablere kontakt mellem den neutrale form af forbindelsen og en tilstrækkelig mængde af den ønskede base i et egnet inert opløsningsmiddel.
DK11154575.2T 2005-02-16 2006-02-16 Biocide boronophthalidforbindelser DK2343304T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65406005P 2005-02-16 2005-02-16
EP06735282.3A EP1853251B1 (en) 2005-02-16 2006-02-16 Halogen-substituted boronophthalides for the treatment of infections

Publications (1)

Publication Number Publication Date
DK2343304T3 true DK2343304T3 (da) 2015-06-29

Family

ID=36917059

Family Applications (3)

Application Number Title Priority Date Filing Date
DK11154575.2T DK2343304T3 (da) 2005-02-16 2006-02-16 Biocide boronophthalidforbindelser
DK18187390.2T DK3424932T3 (da) 2005-02-16 2006-02-16 Bronophthalider til terapeutisk anvendelse
DK15171026.6T DK2987796T3 (da) 2005-02-16 2006-02-16 Halogen-substituerede boronophthalider til behandling af infektioner

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK18187390.2T DK3424932T3 (da) 2005-02-16 2006-02-16 Bronophthalider til terapeutisk anvendelse
DK15171026.6T DK2987796T3 (da) 2005-02-16 2006-02-16 Halogen-substituerede boronophthalider til behandling af infektioner

Country Status (26)

Country Link
US (11) US7582621B2 (da)
EP (4) EP2343304B1 (da)
JP (6) JP5038912B2 (da)
KR (4) KR101456815B1 (da)
CN (2) CN101160124A (da)
AU (3) AU2006214247C1 (da)
BE (1) BE2020C531I2 (da)
BR (1) BRPI0608431B8 (da)
CA (1) CA2597982C (da)
CY (3) CY1120695T1 (da)
DK (3) DK2343304T3 (da)
ES (4) ES2540966T3 (da)
FR (1) FR20C1024I2 (da)
HU (4) HUE040060T2 (da)
IL (2) IL207156A (da)
LT (1) LTC2343304I2 (da)
LU (1) LUC00157I2 (da)
MX (1) MX369262B (da)
NL (1) NL301049I2 (da)
NZ (3) NZ560448A (da)
PL (4) PL1853251T3 (da)
PT (4) PT2343304E (da)
RU (3) RU2414906C2 (da)
SI (3) SI3424932T1 (da)
WO (1) WO2006089067A2 (da)
ZA (4) ZA200707408B (da)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820186B2 (en) * 2001-12-21 2010-10-26 Galderma Research & Development Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt
EP2343304B1 (en) * 2005-02-16 2015-06-10 Anacor Pharmaceuticals, Inc. Biocidal boronophthalide compounds
US7793666B2 (en) * 2005-07-28 2010-09-14 Innovation Biomedical Devices, Inc. Apparatus and method for treatment of infected nail
KR20080110984A (ko) 2005-12-30 2008-12-22 아나코르 파마슈티칼스 인코포레이티드 보론함유 소분자
PT1988779E (pt) 2006-02-16 2015-09-04 Anacor Pharmaceuticals Inc Moléculas pequenas contendo boro como agentes antiinflamatórios
EP2015757A4 (en) * 2006-05-02 2011-01-26 Anacor Pharmaceuticals Inc HYDROLYSERESISTENT, BOROYED THERAPEUTIC USES
EP1900378A1 (en) * 2006-08-31 2008-03-19 Novartis AG Pharmaceutical compositions for the treatment of fungal infections
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
FR2910321B1 (fr) 2006-12-21 2009-07-10 Galderma Res & Dev S N C Snc Gel creme comprenant au moins un retinoide et du peroxyde de benzole
FR2910320B1 (fr) * 2006-12-21 2009-02-13 Galderma Res & Dev S N C Snc Emulsion comprenant au moins un retinoide et du peroxyde de benzole
JO3396B1 (ar) * 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
JP2015178508A (ja) * 2008-01-09 2015-10-08 アナコール ファーマシューティカルズ，インコーポレイテッド 抗炎症剤としてのホウ素含有小分子
WO2009111676A2 (en) * 2008-03-06 2009-09-11 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-inflammatory agents
KR20150065941A (ko) 2008-03-06 2015-06-15 아나코르 파마슈티칼스 인코포레이티드 소염제로써 붕소가 함유된 소분자
CA2721060A1 (en) 2008-04-09 2009-10-15 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
EP2285384A4 (en) * 2008-05-12 2012-04-25 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
WO2010011354A2 (en) * 2008-07-25 2010-01-28 Innovation Biomedical Devices, Inc. Enchanced trans-keratin drug delivery
WO2010028005A1 (en) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
EP2348863A4 (en) 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
WO2010045503A1 (en) * 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
WO2010080558A1 (en) * 2008-12-17 2010-07-15 Anacor Pharmaceuticals, Inc. Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol
WO2010118155A1 (en) * 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010118159A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
MX2012001156A (es) * 2009-07-28 2012-05-08 Anacor Pharmaceuticals Inc Moleculas que contienen boro trisustituidas.
AP4039A (en) 2009-08-14 2017-02-28 Daitao Chen Boron-containing small molecules as antiprotozoal agents
WO2011019616A1 (en) 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011019612A1 (en) 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011022337A1 (en) 2009-08-19 2011-02-24 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
US20110124597A1 (en) * 2009-09-25 2011-05-26 Anacor Pharmaceuticals, Inc. Boron containing small molecules
US8979820B2 (en) 2009-10-09 2015-03-17 Cynthia S. Bailey Method and apparatus for improving the appearance of nails affected by onychomycosis through the topical application of an aqueous solution containing boric acid and camphor or other terpenes
WO2011049971A1 (en) 2009-10-20 2011-04-28 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011060196A1 (en) 2009-11-11 2011-05-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2011063293A1 (en) 2009-11-20 2011-05-26 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antihelminth agents
WO2011094450A1 (en) 2010-01-27 2011-08-04 Anacor Pharmaceuticals, Inc Boron-containing small molecules
RU2015143910A (ru) 2010-02-03 2018-12-28 Инфинити Фармасьютикалз, Инк. Ингибиторы амид-гидролазы жирных кислот
AP2012006482A0 (en) 2010-03-19 2012-10-31 Anacor Pharmacueticals Inc Boron-containing small molecules as anti-protozoalagent
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
RU2432158C1 (ru) * 2010-07-28 2011-10-27 Закрытое акционерное общество "Институт прикладной нанотехнологии" Профилактический бактерицидный лак для обработки ногтей
RS60310B1 (sr) 2010-08-10 2020-07-31 Rempex Pharmaceuticals Inc Ciklični derivati estra boronske kiseline, postupak za pripremu injihove terapeutske upotrebe
SI3251678T1 (sl) 2010-09-07 2022-01-31 Anacor Pharmaceuticals, Inc. Derivati benzoksaborola za zdravljenje bakterijskih okužb
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US9162999B2 (en) 2011-09-28 2015-10-20 Wisconsin Alumni Research Foundation Catalytic conversion of cellulose to fuels and chemicals using boronic acids
CN108142434A (zh) * 2011-10-07 2018-06-12 先正达参股股份有限公司 用于保护有用植物或植物繁殖材料的方法
AR088668A1 (es) * 2011-11-21 2014-06-25 Lilly Co Eli Moleculas pequeñas que contienen boro
AR088669A1 (es) 2011-11-21 2014-06-25 Lilly Co Eli Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2014007831A1 (en) 2012-07-06 2014-01-09 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
KR20150103270A (ko) 2013-01-04 2015-09-09 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
KR20150103269A (ko) 2013-01-04 2015-09-09 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
US9585396B2 (en) 2013-01-30 2017-03-07 Agrofresh Inc. Volatile applications against pathogens
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
US8669207B1 (en) 2013-01-30 2014-03-11 Dow Agrosciences, Llc. Compounds and compositions
MA38319A1 (fr) * 2013-01-30 2016-08-31 Dow Agrosciences Llc Utilisation des benzoxaboroles à titre d'agents antimicrobiens volatils sur les viandes, les plantes, ou des parties de plantes
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9598443B2 (en) 2013-02-01 2017-03-21 Anacor Pharmaceuticals, Inc. Boron containing small molecules as antiprotozoal agents
AR094961A1 (es) 2013-03-15 2015-09-09 Lilly Co Eli 1-hidroxi-benzooxaboroles como agentes antiparasitarios
AU2014202928B1 (en) * 2013-06-05 2014-09-11 Agrofresh Inc. Compounds and compositions
CN104224810B (zh) * 2013-06-20 2017-04-19 中国科学院上海生命科学研究院 一种化合物及其衍生物治疗肺炎球菌感染性疾病的用途
KR101636431B1 (ko) 2013-07-30 2016-07-05 동아에스티 주식회사 트리사이클릭 벤즈옥사보롤 화합물, 이의 제조방법 및 용도
US20160251380A1 (en) * 2013-08-09 2016-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Tricyclic benzoxaborole compounds and uses thereof
AU2014329421B2 (en) 2013-10-03 2018-08-02 Dow Pharmaceutical Sciences, Inc. Stabilized efinaconazole compositions
JP6611014B2 (ja) 2013-11-22 2019-11-27 ボシュ ヘルス アイルランド リミテッド 抗感染方法、抗感染組成物、および抗感染装置
AR099469A1 (es) * 2014-02-17 2016-07-27 Syngenta Participations Ag Fungicidas derivados de oxoborazoles
US10065029B2 (en) 2014-03-03 2018-09-04 Cook Medical Technologies Llc Mechanical dilator
SI3140310T1 (sl) 2014-05-05 2020-01-31 Rempex Pharmaceuticals, Inc. Sinteza boronatnih soli in njihova uporaba
JP2015212249A (ja) * 2014-05-05 2015-11-26 アナコール ファーマシューティカルズ，インコーポレイテッド 化合物および爪光沢剤
EP3139930B1 (en) 2014-05-05 2024-08-14 Melinta Therapeutics, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
EP3148551B1 (en) * 2014-05-12 2021-09-29 AgroFresh Inc. Volatile applications against pathogens
WO2015179308A1 (en) 2014-05-19 2015-11-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EA201692301A1 (ru) 2014-07-01 2017-06-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
EP3164404B1 (en) 2014-07-01 2019-04-03 Daiichi Sankyo Company, Limited Tricyclic benzoxaboroles as antibacterial agents
DK3209319T3 (da) 2014-10-21 2021-10-04 Hexima Ltd En fremgangsmåde til behandling af svampeinfektioner
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
MA41494B1 (fr) 2015-02-12 2020-10-28 Glaxosmithkline Ip No 2 Ltd Composés benzoxaborole substitués en position 4 et utilisations associées
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
KR101580077B1 (ko) * 2015-03-28 2015-12-24 한국콜마주식회사 시크로피록스 함유 네일락카 조성물
US9737075B2 (en) * 2015-04-09 2017-08-22 The Penn State Research Foundation Synergistic benzoxaborole-containing anti-fungicidal composition
HK1245277A1 (zh) 2015-04-09 2018-08-24 Anacor Pharmaceuticals, Inc. 作为抗原虫剂的含硼小分子
US11174267B2 (en) 2015-06-12 2021-11-16 The Regents Of The University Of California Spiroindolinones and therapeutic uses thereof
WO2017024022A1 (en) * 2015-08-06 2017-02-09 The Penn State Research Foundation Benzoxaborole-containing coating resistant to cellulose-supportable fungus
CN106467557B (zh) * 2015-08-18 2019-05-03 北京海美桐医药科技有限公司 他瓦硼罗的一种制备方法
SG10202112628UA (en) 2015-11-30 2021-12-30 Anacor Pharmaceuticals Inc Topical pharmaceutical formulations for treating inflammatory-related conditions
WO2017151492A1 (en) * 2016-03-02 2017-09-08 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
CN109195608B (zh) * 2016-03-02 2021-05-11 比尔及梅琳达盖茨基金会 含硼小分子
US10874679B2 (en) 2016-03-02 2020-12-29 Bill & Melinda Gates Foundation Boron-containing small molecules
AU2017229096A1 (en) 2016-03-07 2018-09-06 Agrofresh Inc. Vaporized administration of pesticides
RS64770B1 (sr) 2016-03-07 2023-11-30 Agrofresh Inc Sinergistički postupci upotrebe jedinjenja benzoksaborola i gasova za prezerviranje kao antimikrobnih agenasa za useve
WO2017193914A1 (zh) * 2016-05-09 2017-11-16 苏州科睿思制药有限公司 克立硼罗游离形式的晶型及其制备方法和用途
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
ES2894251T3 (es) 2016-06-30 2022-02-14 Qpex Biopharma Inc Derivados de ácido borónico y usos terapéuticos de los mismos
WO2018013655A1 (en) 2016-07-12 2018-01-18 Pliva Hrvatska D.O.O. Solid state forms of crisaborole
US10743232B1 (en) 2016-11-15 2020-08-11 Sprint Spectrum L.P. Controlling handover based on carrier-aggregation policies and UE capabilities
WO2018115362A1 (en) 2016-12-22 2018-06-28 Laboratorios Lesvi, Sl Process for preparing 4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl)oxy]benzonitrile (crisaborole)
GB201701583D0 (en) * 2017-01-31 2017-03-15 Drug Delivery Solutions Ltd Topical composition
WO2018150327A1 (en) * 2017-02-14 2018-08-23 Wavelength Enterprises Ltd Crisaborole production process
WO2018164959A1 (en) * 2017-03-09 2018-09-13 The Penn State Research Foundation Boron-containing small molecules for inhibiting activity of a receptor-like protein tyrosine phosphatase
WO2018207216A1 (en) 2017-05-12 2018-11-15 Biophore India Pharmaceuticals Pvt. Ltd. Novel process for the preparation of 4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl) oxy] benzonitrile (crisaborole)
WO2018216032A1 (en) * 2017-05-23 2018-11-29 Msn Laboratories Private Limited, R&D Center Process for the preparation of 5-(4-cyanophenoxy)-1,3-dihydro-1-hydroxy-[2,1]-benzoxaborole and polymorphs thereof
MX2020003495A (es) 2017-10-11 2020-09-18 Qpex Biopharma Inc Derivados de acido boronico y sintesis de los mismos.
CA3080891A1 (en) 2017-11-02 2019-05-09 Halcyon Labs Private Limited Novel process for the preparation tavaborole and its intermediates
MX2020005464A (es) 2017-11-30 2020-12-03 Boragen Inc Compuestos de benzoxaborol y formulaciones de los mismos.
US10329311B1 (en) 2017-12-21 2019-06-25 Olon S.P.A. Process for the preparation of crisaborole
CN108148085B (zh) * 2018-01-04 2019-11-01 合肥医工医药股份有限公司 具有抑制磷酸二酯酶4的化合物、制法及其药物用途
PL3737685T3 (pl) 2018-01-09 2023-10-02 Halcyon Labs Private Limited Sposób wytwarzania kryzaborolu i jego związków pośrednich
US10597410B2 (en) 2018-02-02 2020-03-24 Dipharma Francis S.R.L. Intermediates and process for the preparation of a crystalline form of a topical anti-inflammatory agent
CN108451898A (zh) * 2018-04-03 2018-08-28 苏州尚宜佳生物科技有限公司 一种克立硼罗温敏凝胶剂及其制备方法和应用
US12016868B2 (en) 2018-04-20 2024-06-25 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
GB201809378D0 (en) * 2018-06-07 2018-07-25 Glaxosmithkline Ip Dev Ltd Novel compounds
CN108659024A (zh) * 2018-07-24 2018-10-16 武汉轻工大学 克立硼罗的制备方法
JP7268132B2 (ja) * 2018-07-31 2023-05-02 エムシー２・セラピューティクス・リミテッド 局所用組成物
WO2020041200A1 (en) * 2018-08-18 2020-02-27 Boragen Inc. Solid forms of substituted benzoxaborole and compositions thereof
CR20210163A (es) * 2018-10-05 2021-06-24 Pfizer Inhibidores de pde4 que contienen boro
CN113924084A (zh) 2019-03-20 2022-01-11 瑞塔·多布迈尔 药物组合物
US12065456B2 (en) * 2019-07-25 2024-08-20 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Boron-containing pharmacophore
CN110664756B (zh) * 2019-10-09 2020-11-17 吉林大学 一种小儿外伤喷雾剂及其制备方法
BR112022022367A2 (pt) 2020-05-05 2023-01-10 Qpex Biopharma Inc Derivados e síntese de ácido borônico, formas polimórficas e usos terapêuticos dos mesmos
EP4204012A1 (en) 2020-08-31 2023-07-05 Pfizer Inc. Methods of protecting rna
CN114644645B (zh) * 2022-03-08 2023-05-26 南京农业大学 3-吲哚取代苯硼唑类化合物及其制备方法和应用
CA3239096A1 (en) * 2022-06-23 2023-12-28 Shanghai Micurx Pharmaceutical Co., Ltd. Methods and uses of boron compounds in the treatment of nontuberculous mycobacterium infections and pharmaceutical compositions for treatment of same
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2260336A (en) 1939-10-16 1941-10-28 Dow Chemical Co Method of preparation of organic borates
US3686398A (en) 1970-07-20 1972-08-22 Chevron Res 10,9-boroxarophenanthrene as fungicides
GB1396904A (en) * 1972-08-11 1975-06-11 Ici Ltd Method for the control of micro-organisms
US4602011A (en) 1975-10-24 1986-07-22 Chapman Chemical Company Antimicrobial compositions and methods of using same
US4766113A (en) 1975-10-24 1988-08-23 Chapman Chemical Company Antimicrobial compositions and methods of using same
US4716035A (en) 1985-05-24 1987-12-29 The Procter & Gamble Company Oral compositions and methods for treating gingivitis
US5962498A (en) 1986-06-11 1999-10-05 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. C. indolactam structural-types with anti-inflammatory activity
US4894220A (en) 1987-01-30 1990-01-16 Colgate-Palmolive Company Antibacterial antiplaque oral composition
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
SG47101A1 (en) 1992-07-31 1998-03-20 Us Bioscience Crystalline amifostine compositions and methods for the preparation and use of same
US5348948A (en) 1993-05-07 1994-09-20 American Cyanamid Company 2,2-diaryl-1-(oxa and thia)-2a-azonia-2-borataacenaphthene fungicidal
US5348947A (en) 1993-05-07 1994-09-20 American Cyanamid Company Diarylboron ester and thioester fungicidal agents
US5594151A (en) 1994-01-28 1997-01-14 Prolinx, Inc. Phenylboronic acid complexing reagents derived from aminosalicylic acid
GB9411587D0 (en) * 1994-06-09 1994-08-03 Zeneca Ltd Compound, composition and use
US5688258A (en) 1995-05-02 1997-11-18 The Procter & Gamble Company Disposable cover for an absorbent materials
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
GB9500856D0 (en) * 1995-01-17 1995-03-08 Zeneca Ltd Composition and use
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
US6766183B2 (en) 1995-11-22 2004-07-20 Medtronic Minimed, Inc. Long wave fluorophore sensor compounds and other fluorescent sensor compounds in polymers
GB9604926D0 (en) 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
JP4373497B2 (ja) 1996-06-19 2009-11-25 ローン−プーラン・ロレ・リミテツド 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用
US5831046A (en) 1996-08-05 1998-11-03 Prolinx, Incorporated Boronic acid-contaning nucleic acid monomers
WO1998012206A1 (en) 1996-09-19 1998-03-26 The Board Of Trustees Of Leland Stanford Jr. University Dna adenine methyltransferases and uses thereof
EP0947498B1 (en) 1996-12-02 2004-09-15 Chisso Corporation Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for preparing the same
US6221640B1 (en) 1997-05-14 2001-04-24 Cubist Pharmaceuticals, Inc. Enterococcal aminoacyl-trna synthetase proteins, nucleic acids and strains comprising same
US6140328A (en) 1997-12-12 2000-10-31 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
DE19829947A1 (de) 1998-07-04 2000-01-05 Bayer Ag Elektrolumineszierende Anordnungen mit Bor-Chelaten
US6462036B1 (en) 1998-11-06 2002-10-08 Basf Aktiengesellschaft Tricyclic pyrazole derivatives
AU762992B2 (en) 1998-11-06 2003-07-10 Abbott Gmbh & Co. Kg Tricyclic pyrazole derivatives
EP1155698A4 (en) 1999-01-29 2003-01-15 Nitto Kasei Co Ltd ORGANOBORAL COMPOUNDS HAVING COCCIDIOSTAT ACTIVITY
EP1181291A2 (en) 1999-05-25 2002-02-27 The Penn State Research Foundation Dna methyltransferase inhibitors
US6306628B1 (en) 1999-08-25 2001-10-23 Ambergen, Incorporated Methods for the detection, analysis and isolation of Nascent proteins
CA2383554C (en) 1999-08-25 2008-03-18 Ambergen, Inc. Methods for the detection, analysis and isolation of nascent proteins
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
WO2001025226A1 (en) 1999-10-05 2001-04-12 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
EP1246629A4 (en) * 2000-01-06 2007-04-18 Marantech Holding Llc METHODS USING ACTIVE ELECTRON COMPOUNDS FOR MANAGING CANCER CONDITIONS
US6521619B2 (en) 2000-06-29 2003-02-18 Icos Corporation Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
AU7593001A (en) 2000-07-14 2002-01-30 Zycos Inc Alpha-msh related compounds and methods of use
EP1332131A2 (en) 2000-11-07 2003-08-06 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
WO2002044184A2 (en) 2000-11-30 2002-06-06 The Penn State Research Foundation Dna methyl transferase inhibitors
DE10110051C2 (de) 2001-03-02 2003-07-03 Clariant Gmbh Verfahren zur Herstellung von Boron- und Borinsäuren
ATE438615T1 (de) 2001-04-06 2009-08-15 Biocryst Pharm Inc Biarylverbindungen als serinproteaseinhibitoren
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
DE10143979A1 (de) 2001-09-07 2003-03-27 Clariant Gmbh Verfahren zur Herstellung von Bisallylboranen und nicht-aromatischen Boronsäuren
WO2003033002A1 (en) 2001-10-11 2003-04-24 Ono Pharmaceutical Co Intracellular calcium concentration increase inhibitors
EP1463739A2 (en) 2002-01-10 2004-10-06 The Pennsylvania State Research Foundation Methods for the preparation of alkyl diaryl borinates and complexed diarylborinic acids
WO2004004661A2 (en) 2002-07-09 2004-01-15 Point Therapeutics, Inc. Boroproline compound combination therapy
AU2003291403A1 (en) 2002-11-08 2004-06-03 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
US7446236B2 (en) 2002-12-02 2008-11-04 Solvias Ag Catalytic hydrogenation of carbon-heteroatom double bonds
EP1980564A1 (en) 2002-12-18 2008-10-15 Anacor Pharmaceuticals, Inc. Antibiotics containing borinic acid complexes and methods of use
US7390806B2 (en) 2002-12-18 2008-06-24 Anacor Pharmaceuticals, Inc. Antibiotics containing borinic acid complexes and methods of use
EP1613625A1 (en) 2003-03-14 2006-01-11 AstraZeneca AB Novel fused triazolones and the uses thereof
US20050125852A1 (en) 2003-05-09 2005-06-09 Sugen, Inc. Novel kinases
BRPI0411582A (pt) 2003-06-16 2006-08-08 Anacor Pharmaceuticals Inc substáncias terapêuticas contendo boro hidroliticamente resistentes e método de uso
JP2005022986A (ja) * 2003-06-30 2005-01-27 Sankyo Co Ltd Ｅｄｇ受容体拮抗作用を有するアルキン誘導体
RU2347777C2 (ru) 2003-07-03 2009-02-27 Ф.Хоффманн-Ля Рош Аг Двойные агонисты nk1/nk3 для лечения шизофрении
JP2007530450A (ja) 2003-12-29 2007-11-01 スリーエム イノベイティブ プロパティズ カンパニー ピペラジン、［１，４］ジアゼパン、［１，４］ジアゾカン、および［１，５］ジアゾカン縮合イミダゾ環化合物
EP1755661B1 (en) 2004-05-12 2014-03-12 The Brigham And Women's Hospital, Inc. Gelsolin for use in treating infections
AR049915A1 (es) 2004-06-14 2006-09-13 Anacor Pharmaceuticals Inc Compuestos con contenido de boro y metodos de uso de los mismos
KR100624238B1 (ko) 2004-06-22 2006-09-19 한국화학연구원 알파-아릴메톡시아크릴레이트 유도체를 함유하는 대사성골 질환의 예방 및 치료용 약학 조성물
US20060111388A1 (en) 2004-11-19 2006-05-25 University Of North Texas Health Science Center At Fort Worth Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
GB0501944D0 (en) 2005-01-31 2005-03-09 Univ Cambridge Tech Compounds for use in chemical detection and/or quantitation
EP2343304B1 (en) 2005-02-16 2015-06-10 Anacor Pharmaceuticals, Inc. Biocidal boronophthalide compounds
EP1856113B1 (en) 2005-03-08 2016-01-06 Agency for Science, Technology and Research Chiral bisoxazoline catalysts
UY29449A1 (es) 2005-03-30 2006-10-02 Astion Dev As Tratamiento de enfermedades dermatólogicas y del prurito.
WO2007022437A2 (en) 2005-08-18 2007-02-22 Auspex Pharmaceuticals, Inc. Therapeutic agents for the treatment of cancer and metabolic disorders
KR20080110984A (ko) 2005-12-30 2008-12-22 아나코르 파마슈티칼스 인코포레이티드 보론함유 소분자
PT1988779E (pt) 2006-02-16 2015-09-04 Anacor Pharmaceuticals Inc Moléculas pequenas contendo boro como agentes antiinflamatórios
RU2008152367A (ru) 2006-06-12 2010-07-20 Анакор Фармасьютикалз, Инк. (Us) Соединения для лечения периодонтального заболевания
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
KR100848491B1 (ko) 2007-01-16 2008-07-28 영진약품공업주식회사 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법
JO3396B1 (ar) 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
KR100895300B1 (ko) 2007-07-20 2009-05-07 한국전자통신연구원 생체신호 측정의복과 생체신호 처리시스템
WO2009111676A2 (en) 2008-03-06 2009-09-11 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-inflammatory agents
KR20150065941A (ko) 2008-03-06 2015-06-15 아나코르 파마슈티칼스 인코포레이티드 소염제로써 붕소가 함유된 소분자
EP2285384A4 (en) 2008-05-12 2012-04-25 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
WO2010028005A1 (en) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2010045505A1 (en) 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-protozoal agents
WO2010045503A1 (en) 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
AR088669A1 (es) * 2011-11-21 2014-06-25 Lilly Co Eli Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos
AR088668A1 (es) * 2011-11-21 2014-06-25 Lilly Co Eli Moleculas pequeñas que contienen boro

Also Published As

Publication number Publication date
EP3424932A1 (en) 2019-01-09
ES2540966T3 (es) 2015-07-15
CN101160124A (zh) 2008-04-09
BE2020C531I2 (da) 2025-09-05
KR101426220B1 (ko) 2014-08-05
AU2010203096C1 (en) 2012-09-20
RU2606947C2 (ru) 2017-01-10
PT3424932T (pt) 2021-05-19
US20060234981A1 (en) 2006-10-19
RU2007134429A (ru) 2009-03-27
HK1109735A1 (en) 2008-06-20
JP5038912B2 (ja) 2012-10-03
EP1853251B1 (en) 2013-04-24
LUC00157I2 (da) 2021-07-06
EP2987796B1 (en) 2018-08-08
NZ578297A (en) 2010-11-26
US20130244980A1 (en) 2013-09-19
PT2987796T (pt) 2018-10-18
RU2010133524A (ru) 2012-02-20
CN101914109A (zh) 2010-12-15
HK1221956A1 (en) 2017-06-16
JP2013018778A (ja) 2013-01-31
ES2414095T3 (es) 2013-07-18
CY1124503T1 (el) 2022-07-22
US20100190748A1 (en) 2010-07-29
EP2343304A1 (en) 2011-07-13
NZ598441A (en) 2013-07-26
US7582621B2 (en) 2009-09-01
AU2011200994A1 (en) 2011-03-31
FR20C1024I1 (da) 2020-07-31
AU2010203096A1 (en) 2010-08-12
BRPI0608431A2 (pt) 2009-12-29
JP6046876B2 (ja) 2016-12-21
US20160108063A1 (en) 2016-04-21
SI2343304T1 (sl) 2015-08-31
BRPI0608431B1 (pt) 2020-09-15
CY1120695T1 (el) 2019-12-11
KR101337068B1 (ko) 2013-12-06
WO2006089067A2 (en) 2006-08-24
NZ560448A (en) 2009-08-28
DK3424932T3 (da) 2021-05-25
IL185080A0 (en) 2008-08-07
DK2987796T3 (da) 2018-09-17
IL185080A (en) 2012-07-31
CA2597982A1 (en) 2006-08-24
BRPI0608431B8 (pt) 2021-05-25
ES2872962T3 (es) 2021-11-03
EP3424932B1 (en) 2021-04-07
NL301049I1 (nl) 2020-07-01
CN101914109B (zh) 2014-07-23
US20150065459A1 (en) 2015-03-05
ZA200905950B (en) 2010-11-24
KR101337045B1 (ko) 2013-12-05
US20190330245A1 (en) 2019-10-31
SI3424932T1 (sl) 2021-08-31
EP1853251A2 (en) 2007-11-14
AU2006214247A1 (en) 2006-08-24
CY2020027I2 (el) 2021-01-27
SI2987796T1 (sl) 2018-11-30
AU2010203096B2 (en) 2010-12-02
HUE054365T2 (hu) 2021-09-28
MX369262B (es) 2019-11-04
HUE026021T2 (en) 2016-05-30
AU2006214247B2 (en) 2010-08-05
PL3424932T3 (pl) 2021-09-20
HUE040060T2 (hu) 2019-02-28
KR20070112390A (ko) 2007-11-23
PT2343304E (pt) 2015-08-26
PL2987796T3 (pl) 2018-12-31
PL1853251T3 (pl) 2013-09-30
IL207156A (en) 2014-04-30
RU2414906C2 (ru) 2011-03-27
CA2597982C (en) 2014-07-08
ES2686981T3 (es) 2018-10-23
EP1853251A4 (en) 2010-01-13
FR20C1024I2 (fr) 2021-07-09
JP2014132031A (ja) 2014-07-17
US20110319361A1 (en) 2011-12-29
EP2343304B1 (en) 2015-06-10
US8440642B2 (en) 2013-05-14
AU2006214247C1 (en) 2012-11-08
JP2010248265A (ja) 2010-11-04
LTC2343304I2 (lt) 2022-11-10
HK1160139A1 (en) 2012-08-10
US8889656B2 (en) 2014-11-18
PT1853251E (pt) 2013-07-19
ZA200707408B (en) 2009-11-25
HUS2000019I1 (hu) 2020-07-28
RU2016145916A (ru) 2018-05-23
JP2017105826A (ja) 2017-06-15
KR101456815B1 (ko) 2014-10-31
US20190048026A1 (en) 2019-02-14
US20140142064A1 (en) 2014-05-22
KR20130095330A (ko) 2013-08-27
ZA201506944B (en) 2018-08-29
KR20100105869A (ko) 2010-09-30
LTPA2020524I1 (lt) 2020-09-10
PL2343304T3 (pl) 2015-09-30
ZA201005380B (en) 2016-08-31
LUC00157I1 (da) 2020-06-08
JP2008535781A (ja) 2008-09-04
US20210070780A1 (en) 2021-03-11
CY2020027I1 (el) 2021-01-27
US8039451B2 (en) 2011-10-18
EP2987796A1 (en) 2016-02-24
US20170066788A1 (en) 2017-03-09
NL301049I2 (nl) 2020-09-10
WO2006089067A3 (en) 2007-07-19
JP2016020374A (ja) 2016-02-04
RU2016145916A3 (da) 2020-07-21
KR20130100019A (ko) 2013-09-06

Similar Documents

Publication Publication Date Title
DK2343304T3 (da) Biocide boronophthalidforbindelser
HK1160139B (en) Biocidal boronophthalide compounds
HK40000784A (en) Boronophthalides for therapeutic use
HK40000784B (en) Boronophthalides for therapeutic use
MX2007009625A (en) Boron-containing small molecules